Buflomedil for intermittent claudication

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 3, 2013, Pages

  de Backer, Tine Lm ^a,b   Vander Stichele, Robert ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BUFLOMEDIL; PLACEBO; PYRROLIDINE DERIVATIVE; VASODILATOR AGENT;

DIABETIC PATIENT; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG RESPONSE; EXERCISE TEST; HUMAN; INTERMITTENT CLAUDICATION; MAXIMUM WALKING DISTANCE; PAIN FREE WALKING DISTANCE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WALKING; DOUBLE BLIND PROCEDURE; ORAL DRUG ADMINISTRATION; PUBLISHING; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; HUMANS; INTERMITTENT CLAUDICATION; PUBLICATION BIAS; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASODILATOR AGENTS;

MLCS; MLOWN;

EID: 84880080761     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD000988.pub4     Document Type: Review

References (41)

1. Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis SA. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. International Angiology 2001;20(4):337-44.
2. Diamantopoulos EJ, Raptis SA, Christodoulou-Peters M, Moulopoulos SD. Controlled trial of buflomedil in diabetic peripheral occlusive disease. Ischaemic Diseases and the Microcirculation. New Results. International Symposium. Frankfurt, January 1989:80-4.
3. Trubestein G, Balzer K, Bisler H, Kluken N, Mahfoud Y, Muller-Wiefel H, et al.Buflomedil in obstructive arterial disease: Results of a controlled trial [Buflomedil bei arterieller Verschlusskrankheit: Ergebnissse einer kontrollierten Studie]. Deutsche Medizinische Wochenschrift 1982;107(51-52):1957-61.
4. Trübestein G, Balzer K, Bisler H, Klüken N, Muller-Wiefel H, Unkel B, et al.Buflomedil in arterial occlusive disease: results of a controlled multicenter study. Angiology 1984;35(8):500-5.
5. Bisler H. Clinical response to buflomedil in arterial occlusive disease. Therapiewoche 1983;33:2204-10.
6. Fonseca V, Mikhaildis DP, Barradas MA, Jeremy JY, Gracey L, Dandona P. Double-blind placebo-controlled trial of buflomedil in intermittent claudication. International Journal of Clinical Pharmacology Research 1988;8(5):377-81.
7. Levien . [Unpublished study] W80-BU-004LJL. S-Africa, 1983. Mentioned in: Walker GA, Mac Hannaford JC. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387-94.
8. Leizorovicz A. Buflomedil reduces amputations in patients with peripheral arterial occlusive disease. American College of Cardiology, 54th Annual Scientific Session, Late-Breaking Clinical Trials; 2005 Mar 6-9; Orlando, Florida 2005.
9. Limbs International Medicinal Buflomedil (LIMB) Study Group, Leizorovicz, A, Becker F. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.[see comment]. Circulation 2008;117(6):816-22.
10. Lowe GDO, Dandona P, Horrocks M, Cotton LT. [Unpublished study] Evaluation of the clinical efficacy and safety of oral buflomedil hydrochloride in the treatment of intermittent claudication. Study QL/UK.83/2-5. UK, 1987. Mentioned in: Walker GA, Mac Hannaford JC. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387-94 (Available from the authors).
11. Lund, et al.[Unpublished study] AB-8603. US, 1988. Mentioned in: Walker GA, Mac Hannaford JC. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387-94.
12. Olsson . [Unpublished study] Sweden, 1986. Mentioned in: Walker GA, Mac Hannaford JC. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387-94.
13. Raithel, et al.[Unpublished study] BU-3-P05. Germany, 1985. Mentioned in: Walker GA, Mac Hannaford JC. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387-94.
14. Zinnagl N. A double blind study of the effects of buflomedil in 40 patients with arterial occlusive disease in Stage IIB [Doppelblindstudie über die Wirksamkeit von Buflomedil an 40 Patienten mit arterieller Verschlusskrankheit im Stadium IIB]. International Symposium on Conservative Therapy of Arterial Occlusive Disease. Bonn, May 23-25. New York: Georg Thieme Verlag, 1986.
15. Baitsch R. [Unpublished study]. BU-2-DO2. Germany, 1983. Mentioned in: Walker GA, Mac Hannaford JC. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995; Vol. 9, issue 4:387-94.
16. Bevan EG, Waller PC, Ramsay LE. Pharmacological approaches to the treatment of intermittent claudication. Drugs and Aging 1992;2(2):125-36.
17. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: critical analysis of the methods and findings of published clinical trials, 1965-1985. British Journal of Clinical Pharmacology 1988;26(5):569-76.
18. Diamantopoulos EJ, Raptis SA, Christodoulou-Peters M, Moulopoulos SD. Controlled trial of buflomedil in diabetic peripheral occlusive disease. Ischaemic diseases and the microcirculation. New results. International Symposium. Frankfurt, January 1989:80-4.
19. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286-91.
20. Fontaine VR, Kim M, Kieny R. Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripheren Durchblutungsstorungen]. Helvetica Chirurgica Acta 1954;5/6:499-533.
21. Gardner MJ, Altman DG. Estimating with confidence. In: Gardner MJ, Altman DG editor(s). Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Publishing Group, 1989:3-5.
22. Gardner MJ, Altman DG. Estimation rather than hypothesis testing: confidence intervals rather than P values. In: Gardner MJ, Altman DG editor(s). Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Publishing Group, 1989:6-19.
23. Altman DG, Gardner MJ. Calculating confidence intervals for means and their differences. In: Gardner MJ, Altman DG editor(s). Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Publishing Group, 1989:20-7.
24. Gardner MJ, Altman DG. Tables for calculation of confidence intervals. In: Gardner MJ, Altman DG editor(s). Statistics with confidence: confidence intervals and statistical guidelines. London: BMJ Publishing Group, 1989:111-29.
25. Jadad RJ, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
26. Jepson RG, Kleijnen J, Leng GC. Garlic for peripheral arterial occlusive disease. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD000095]
27. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database of Systematic Reviews 1998, Issue 1. [DOI: 10.1002/14651858.CD000987]
28. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000990]
29. Liard F, Benichou AC, Gamand S, Lehert P. The effects of naftidrofuryl on quality of life. Disease Management Health Outcomes 1997;2(Suppl 1):71-8.
30. Marimbert J. Lettre aux professionnels de santé: Pharmacovigilance et la sécurité d'emploi du buflomédil [Letter to health professionals: Pharmacovigilance and safety of use of buflomedil]. Agence française de sécurité sanitaire des produits de santé. 13 November 2006.
31. Mulrow CD, Oxman AD. Cochrane Collaboration Handbook (In: The Cochrane Library, Issue 3). Oxford: Update Software, 1999.
32. Price JF, Leng GC. Steroid sex hormones for lower limb atherosclerosis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD000188]
33. Schulz KF, Chalmers IC, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273(5):408-12.
34. Spengel A, Brown TM, Dietze S, Kirchberger I, Comte S. The claudication scale (CLAU-S). New disease-specific quality-of-life instrument in intermittent claudication. Disease Management Health Outcomes 1997;2(Suppl 1):65-70.
35. Verhaeghe R. Epidemiology and prognosis of peripheral obliterative arteriopathy. Drugs 1998;56(suppl 3):1-10.
36. Walker GA, Mac Hannaford JC. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication. Fundamental and Clinical Pharmacology 1995;9(4):387-94.
37. Wood S. Buflomedil to reduce clinical complications of peripheral artery disease? Maybe, maybe not. www.theheart.org/article/402581.do 11 March 2005, issue accessed 26 April 2007.
38. Wurzinger LJ, Schmid-Schonbein H. Effect of buflomedil on epinephrine-enhanced platelet aggregation in vitro and ex vivo. Arzneimittel-Forschung 1987;37(10):1113-5.
39. De Backer TLM, Vander Stichele RH, Bogaert MG. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000988]
40. De Backer TLM, Bogaert MG, Vander Stichele RH. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD000988.pub2]
41. de Backer TLM, Bogaert M, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD000988.pub3]